Smart pill bottles and video visits boost cancer drug adherence

NCT ID NCT04054557

First seen Feb 05, 2026 · Last updated Jun 19, 2026 · Updated 21 times

Summary

This study tested whether using telehealth (video visits with a doctor) and smart pill bottles can help breast cancer patients take their hormone therapy more consistently. 305 women and men with early-stage hormone receptor-positive breast cancer participated. The goal was to see if these tools improve adherence to daily anti-estrogen pills, which can reduce the risk of cancer coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IIA BREAST CANCER AJCC V6 AND V7 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Jefferson Health - Asplundh Cancer Pavilion

    Willow Grove, Pennsylvania, 19090, United States

  • Jefferson Health - Northeast

    Torresdale, Pennsylvania, 19114, United States

  • Jefferson Health - South Jersey

    Washington Township, New Jersey, 08080, United States

  • Methodist Hospital

    Philadelphia, Pennsylvania, 19148, United States

  • Thomas Jefefrson University

    Philadelphia, Pennsylvania, 19107, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

telehealth (video visits with oncologist)

What this could lead to

If successful, this approach could help more breast cancer patients take their hormone therapy as prescribed, potentially reducing the risk of cancer recurrence.

What could go wrong

This is a completed phase II trial, so results are not yet widely confirmed. The intervention focuses on adherence, not on treating the cancer itself, so it may not improve outcomes for all patients.

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast carcinoma in situ breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.